Company Summary

GenBio Inc. is a Delaware S-Corp. incorporated December 28, 2018, with U.S. headquarters in Aliso Viejo, CA.
Our **Mission**

- GenBio Inc aims to rapidly develop an entirely new class of molecules to provide potent anti-inflammatory activity without the gastrointestinal side effects of NSAIDs or the cardiovascular side effects of other inhibitors.

- To address these serious current limitations and become a world leader in a new class of more efficient inhibitor drugs.
A Vision Worth Executing

To be one of the world’s leading companies developing a completely new generation of more efficacious, less toxic, novel and disruptive medicines for the treatment of inflammatory conditions and Covid-19.
1.0 Executive Statement

- **GenBio** is an early-stage US biotechnology company that intends to advance into preclinical trials a novel therapeutic from a largely unknown natural extract.

- **GenBio** aims to be the first company in the world to isolate and fractionate a new molecule based on the remarkable original scientific findings from the USA.

- **USA based research is radical** – GenBio can build on this startling USA research breakthrough and develop an important new class of COX-2 selective/ LOX-5 / LOX 15 triple inhibitors and address a market gap with an entirely new generation of anti-inflammatory products with lower toxicity and increased efficacy due to multiple pathway targeting.

- **Research** demonstrates its blocking cell entry potential as well, thereby denying Covid-19 the ability to complete any reverse transcriptase enzymatic reactions.

- **GenBio** has designed an Investigational New Drug (IND) research program that is highly effective as both an anti-inflammatory agent and as an anti-viral drug to combat Covid-19.
1.0 Continued

- **GenBio** has in place specialized scientific research teams, ready to begin the IND research program once funds are secured

- **The IND program** should see an entirely new generation of more effective anti-inflammatory drugs and fill an urgent market gap

- **Focused exit strategy** within 12/36 months at IND inflexion point (phase 1) or earlier (Discovery Phase)

- **Significant potential ROI** based on conservative financial modelling

- **GenBio** is uniquely placed to be the world’s leading company and identify the core molecule(s) and platform responsible for the far more effective alleviation of numerous medical conditions, including a potential anti-viral drug for Covid-19

- **GenBio** is currently seeking $1,000,000 to fund drug discovery research

- ‘**Series A**’ finance round will follow within 6/12 months
1.1 Objectives

- Advance research without delay to fractionate/isolation phase and identify the molecule(s) at a CRO facility in California
- Protect the Intellectual Property - patent the findings
- Undertake ‘Series A’ funding Round
- Complete the IND program to inflexion point 1
- Effect a trade sale or divest specified assets within 12/36 months with a suitable (Pharmaceutical) Company seeking a new generation of arthritic drugs and / or a Covid-19 anti-viral drug program
1.2 Keys to Success

- Become the first company in the world to identify the specific molecule(s) through isolation and fractionation, building on its unique remarkable original scientific findings from the USA.

- Address a market gap with an entirely new superior generation of anti-inflammatory products with lower toxicity and increased efficacy due to multiple pathways targeting.

- Utilize highly specialized scientific research teams who are ready to begin the research program once funds are secured.

- GenBio has significant and unknown confidential research expertise in this specialised category, unrivaled by any competitor, through its co-founders.

- Focused exit strategy within 12/36 months at IND inflexion point or earlier.
USE OF Funds 12 Months $1,000,000

R&D USA-$ 400,000
Operational- $200,000
Patent Attorneys- $80,000
Legal- Corporate- $40,000
Marketing -$40,000
Accountancy - $30,000
Contingency - $210,000
3.0 Market Needs and Value Proposition

- Current drug treatments often have toxicity issues, along with fast-losing patent protections, whilst also failing to treat the root cause of the disease, instead only concentrating on the symptoms

- GenBio is utilizing its potential proprietary extract platforms to generate novel therapeutic agents for use in multiple and distinct indications. The initial focus is arthritis, but our anti-viral drug program for Covid-19 with the ability to inhibit pro-inflammatory cytokines whilst stimulating anti-inflammatory cytokines, is also receiving significant attention
3.1 Research

- The lead platforms and molecules being developed have been demonstrated to inhibit several complementary neural pathways, enabling far more potent and yet less toxic therapeutic intervention.

- Working in close co-operation with GenBio’s CRO partners, the rational approach to molecular modelling to optimize candidates based on the Company’s core scaffolds, will lead to an improved next generation new treatment modality for medicine, based on cost-effective strategies.

- There is a large market gap for new novel ingredients, backed by rigorous scientific testing, either as a stand-alone pharmacy product or “infused” into existing nutraceutical, pharmaceutical and food brands to increase profit margins and promote human health.
Timeline for ABQ-8187, {Extraction from extract & further work}

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraction and Isolation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analysis of crude fraction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimicrobial test for crude extract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extraction and Isolation in 100 g scale</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolation of major fraction (3-5) from the active extract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testing of Antimicrobial activity of isolated fractions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structural elucidation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patent Analysis, design and synthesis of NCEs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physico chemical properties &amp; Early DMPK studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advanced DMPK studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxicity studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Stage 1: 6 months
- Fractionation/Isolation Identify the active ingredient/s. Establish the chemical structure and nature of the active ingredient/s. (‘lead molecule’).

Stage 2: 12 months
- Medicinal chemistry, CMC and structure-activity relationship (SAR).

Stage 3: 12 months
- IND-enabling murine and dosage/toxicology research

Stage 4: 6 months
- IND Filing FDA
4.0 Competitive Landscape

- Pharmaceutical companies making inhibitor drugs approved for pain and various inflammatory diseases, including Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis, have been limited to one brand still on the U.S. market – Celebrex® (celecoxib, Pfizer). This is a very valuable drug and is the primary reason Pfizer bought Pharmacia in 2002 for $60 billion. There is no question that there is significant market demand for a low-side-effect, novel-class of inhibitor natural extracts, and that the development of such is likely to trigger competing large bids from the numerous international pharmaceutical companies eager to own a patented compound in this currently unoccupied multi-billion-dollar market segment. For comparison purposes, some recent acquisitions of inflammatory / anti-arthritis drugs are:

- Rottapharm was acquired for its arthritis drug (Dona®) and anti-inflammatory drug (Reparil®) for $3B USD
- US rights to Treximet® for migraines bought for $220M USD
- US rights to Pennsaid for osteoarthritis bought for $45M USD
### 4.1 Most relevant inflammatory biotechnology IP licensed or sold at discovery Phase (top 15)

<table>
<thead>
<tr>
<th>Principal Company</th>
<th>Deal Asset Type</th>
<th>Total Milestone At-signing (USD M)</th>
<th>Indications</th>
<th>Deal Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second Genome Inc</td>
<td>Drug, Drug Discovery Technology</td>
<td>550.00</td>
<td>Inflammatory bowel disease (Primary); Fibrosis; Inflammatory disease</td>
<td>06-Apr-2020</td>
</tr>
<tr>
<td>Translate Bio MA Inc</td>
<td>Product(s) only; Drug</td>
<td>750.00</td>
<td>Infectious disease (Primary); Coronavirus disease 19 infection</td>
<td>08-Jun-2018</td>
</tr>
<tr>
<td>Agios Pharmaceuticals Inc</td>
<td>Drug Discovery Technology, Drug</td>
<td>283.90</td>
<td>Autoimmune disease, Cancer; Inflammatory disease</td>
<td>17-May-2016</td>
</tr>
<tr>
<td>Kyvera Therapeutics</td>
<td>Drug; Product(s) only</td>
<td>570.00</td>
<td>Autoimmune disease (Primary); Inflammatory disease</td>
<td>13-Jan-2020</td>
</tr>
<tr>
<td>HOOKIPA Pharma Inc</td>
<td>Drug; Drug Discovery Technology</td>
<td>400.00</td>
<td>Infectious disease (Primary); HIV infection; Hepatitis B virus infection</td>
<td>05-Jun-2018</td>
</tr>
<tr>
<td>Rheos Medicines Inc</td>
<td>Drug Discovery Technology, Drug</td>
<td>560.00</td>
<td>Autoimmune disease (Primary); Inflammatory disease</td>
<td>19-Dec-2019</td>
</tr>
<tr>
<td>Exscientie Ltd</td>
<td>Drug Discovery Technology</td>
<td>273.92</td>
<td>Metabolic disorder (Primary); Diabetes mellitus; Fibrosis; Inflammatory disease</td>
<td>09-May-2017</td>
</tr>
<tr>
<td>Zymeworks Inc</td>
<td>Drug Discovery Technology</td>
<td>902.00</td>
<td>Unidentified indication (Primary); Infectious disease</td>
<td>21-Apr-2016</td>
</tr>
<tr>
<td>Forge Therapeutics Inc</td>
<td>Drug; Drug Discovery Technology</td>
<td>334.00</td>
<td>Infectious disease (Primary)</td>
<td>24-Apr-2019</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corp</td>
<td>Drug; Drug Discovery Technology</td>
<td>1002.00</td>
<td>Cancer (Primary); Autoimmune disease; Infectious disease</td>
<td>19-Dec-2018</td>
</tr>
<tr>
<td>Aduro BioTech Inc</td>
<td>Drug Discovery Technology, Drug</td>
<td>620.00</td>
<td>Autoimmune disease, Inflammatory disease</td>
<td>18-Dec-2018</td>
</tr>
<tr>
<td>Zymeworks Inc</td>
<td>Drug Discovery Technology, Drug</td>
<td>474.50</td>
<td>Dermatological disease (Primary); Autoimmune disease; Inflammatory disease</td>
<td>23-Oct-2018</td>
</tr>
<tr>
<td>Abylnx NV</td>
<td>Drug; Drug Discovery Technology</td>
<td>276.68</td>
<td>Inflammatory disease (Primary); Immune disorder</td>
<td>19-Jul-2017</td>
</tr>
<tr>
<td>IFM Therapeutics Inc</td>
<td>Company</td>
<td>2020.00</td>
<td>Cancer (Primary); Gout; Inflammatory bowel disease; Inflammatory disease; Non-alcoholic steatohepatitis</td>
<td>03-Aug-2017</td>
</tr>
<tr>
<td>MankKind Corp</td>
<td>Drug Discovery Technology</td>
<td>102.25</td>
<td>Inflammatory disease; Neurological disease; Pain</td>
<td>21-Jan-2016</td>
</tr>
</tbody>
</table>
The Directors of GenBio Inc. have discussed ongoing divestment of assets and the future sale of the company at phase 1 inflexion point or even earlier at Discovery Phase with leading international investment bankers and pharmaceutical companies. Pharmaventures LTD, Oxford UK, a world leader in deals and alliances in the biotechnology sector, has monitored progress on the research since May 2012. They have also interviewed a highly qualified scientific team and will continue to monitor and attend monthly board meetings in order to ensure the Company is positioning itself correctly for a commercial trade sale.

5.0 Industry Summary

- The Company will operate in this distinct industry: Research and Development in the Physical, Engineering, and Life Sciences NAICS 541712.
- U.S. Census Bureau. “2017 NAICS.”
- https://www.census.gov/cgi-bin/ssa/naics/naisrch?chart=2017
6. SWOT Analysis

- **Strengths**: Unrivalled expertise / Limited competition / Highly specialised team with experience in category / Qualified management
- **Opportunities**: Market Gap / Sought after product / Huge potential
- **Weaknesses**: Further Scientific personnel will be required / Lack of working capital / Limited patent protection
- **Threats**: Regulatory complications / Research impasse / Global Recession
7.0 Milestones

- Year 1: Identification of the molecule, Platform NCE, NME
- Year 1: Ring fence findings with a suite of provisional patents
- Year 1: Commence Dosage/Toxicology studies
- Year 1: Complete ‘Series A’ finance round
- Year 1: Instruct US Regulatory specialists to commence FDA pre-IND regulatory program
- Year 2: IND research program
- Year 2-3: IND research program
- Year 2-3: Divest Company of the IND molecule / compound
8.0 Management

Giles Tilley, Managing Director

- Giles Tilley has over 35 years of Senior International Business Development & Management experience within the Natural Healthcare industries. Giles has worked closely with the Australian government for more than 15 years identifying innovative natural Australian healthcare products and technologies and guiding them from initial market entry strategy to international success, including working on Australian Manuka Honey in international markets, especially in Germany and Japan.

- He has gained widespread success as an innovative entrepreneur, having stunned Australia by becoming only the second person ever in its history to sell non-alcohol specialized dermaceuticals to NASA shuttle operations in the U.S., a feat which gained him both media attention and a political citation from the Queensland State Premier. He has consulted to Medifruit Pty Ltd since 2010 and driven the Company’s international R&D program, culminating recently in a platform of patents in the pain and inflammatory category.

- Since 2010 he has branched out as a specialist consultant and is retained by GenBio to advise on rare novel extracts for the U.S. market. His expertise is in start-ups and he has guided several to success in his 35-year career in this challenging area. Giles holds both a BA and MA from Oxford University.
Todd D. Sonoga, Director, Chief Marketing Officer

- Todd has successfully represented public and private companies for over 20 years, consulting them on market awareness, support, raising capital, identifying merger and acquisition targets, advertising, marketing & branding. In 1992, Todd was recruited by Wall Street Publishing for their ‘The Small Cap Report,’ out of Newport Beach California where he oversaw research, training, subscriber management and served as Editor of the newsletter.

- Todd in 1998, founded Trilogy Marketing Strategies, Wall Street Microcap in 2013 and Crowdfunding Power in 2014. In early 2017, Todd co-founded and assumed the role of Chief Marketing Officer for WFN1 News Corp. (WFN1) and the show ‘CEO Money’ on Dallas Talk Radio Show on IHeart’s 1190 AM. Currently, Todd also owns and operates one of North America’s largest investor networks, with a total reach of over 10 million investors and is a member or administrator to over 700 investment rooms, groups, boards and affiliate investment websites.
Professor Lindsay Brown, Chief Scientific Officer, Consultant to Board

- Professor Lindsay Brown was until very recently Professor of Biomedical Sciences, University of Southern Queensland, Australia and since 2015 a Fellow of the International Academy of Cardiovascular Science. His 35 years of scientific research encompasses an emphasis on drugs acting on the heart and associated blood vessels, endocrine organs and brain.

- His research team was internationally recognized for using rat models to determine whether interventions, including many natural products, can reverse or prevent disease-induced changes of the heart, liver, kidney and adipose tissue, and to indicate whether these interventions should be further tested in humans with these diseases. His recent studies have characterized the prevention of obesity-induced osteoarthritis in rats. Further, he has reported, including National TV, the decrease in blood pressure in mildly hypertensive patients using Australian Queen Garnet plum juice. He is an editor of Nutrients and Journal of Clinical Medicine. He also holds a USQ Excellence in Research award 2015.
9.0 Return on Investment
This table calculates the return on investment over a three-year period based upon a valuation from the successful Phase 1 IND sale.

<table>
<thead>
<tr>
<th>Return on Investment</th>
<th>$,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of Investment (as at year 1)</td>
<td>6,000</td>
</tr>
<tr>
<td>Return on Investment (as at year 3)</td>
<td>120,000</td>
</tr>
<tr>
<td>Annualised ROI</td>
<td>171%</td>
</tr>
</tbody>
</table>
Project Management (Consultant to board)
Davos Pharma
231 Market Place, Suite 383,
San Ramon, CA 94583

Trade Sale Consultant - Board Advisor (Consultant to board)
Dr Adrian Dawkes (CEO)
Pharmaventures Ltd
Triumph House 1300 Parkway Court
John Smith Drive
Oxford Business Park South | Oxford
OX4 2JY, UK

Accountants
H&R Block
273 W 500 S, Ste 15,
Bountiful, UT 84010

Australian Lead Researcher
[CSO and consultant to board]
Professor Lindsay Brown
University Southern Queensland
Biomedical Science
Ipswich 4305
Qld, Australia

IP & Corporate Attorneys
DLA Piper LLP (US)
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

Regulatory Counsel to FDA Pre-IND Drug application
Camargo Pharmaceutical Services LLC,
9825 Kenwood Rd Ste 203 Cincinnati,
OH 45202
Share Structure - Capitalization

- 18% [Founder]
- 18% [Founder]
- G. Tilley. 7.5% [Founder]
- D. Tilley. 7.5% [Founder]
- Y. Tilley. 7.5% [Founder]
- R. Tilley. 7.5% [Founder]
- T. Sonoga. 15% [Founder]
- T. Hernandez. 15% [Founder]
- 4% [Founder]
- 10 Million shares allocated
- 80 million shares to be authorized

Original capital structure as advised by Foley Hoag Lawyers, Boston, Ma.
Be one of the very few to capitalize on this exciting new discovery

Contact us @

genbioinc@gmail.com

www.genbioinc.com

949-716-6030
Thank You!